Article

Polares Medical has secured $50 million in a Series C funding round, backed by DC Global Ventures, Lumination Partners, existing investors, and a new strategic investor. This funding will advance the clinical studies of the MR mitral valve replacement system, which addresses the complexities of mitral regurgitation treatment.

The system has been implanted in over 70 patients, validating its concept and generating promising results. The raised funds will support further clinical studies in the US, Europe, and Australia.